|
|
|
|
Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Topotecan Teva
International Nonproprietary Name (INN): topotecan LONDON, June 25, 2009-On 25 June 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion,** recommending to grant a marketing authorisation for the...
|
|
|
BRIEF-Teva gets EU backing for generic cancer drug
* EU medicines agency says recommends generic version of Hycamtin from Teva (London Equities Newsroom; +44 20 7542 7717) COPYRIGHT Copyright Thomson Reuters 2009.All rights reserved. The copying, republication or redistribution of...
|
|
|
EU Panel Recommends ChondroCelect Get Marketing Authorisation
LONDON -(Dow Jones)- The Committee for Medicinal Products for Human Use Friday adopted its first positive opinion for an advanced therapy medicinal product, recommending that ChondroCelect, from TiGenix NV, be granted a marketing...
|
|
|
EU Panel Recommends ChondroCelect Get Marketing Authorisation
LONDON -(Dow Jones)- The Committee for Medicinal Products for Human Use Friday adopted its first positive opinion for an advanced therapy medicinal product, recommending that ChondroCelect, from TiGenix NV, be granted a marketing...
|
|
|
EU Panel Recommends ChondroCelect Be Gra
LONDON (Dow Jones)--The Committee for Medicinal Products for Human Use Friday adopted its first positive opinion for an advanced therapy medicinal product, recommending that ChondroCelect, from TiGenix NV, be granted a marketing...
|
|
|
EU Panel Grants Marketing Authorisation To Afinitor
LONDON -(Dow Jones)- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions, recommending the granting of a marketing authorisation, for Afinitor, Mozobil and Samsca.MAIN FACTS: ...
|
|
|
EU Panel Grants Marketing Authorisation To Afinitor
12:50 PM EDT L LONDON -(Dow Jones)- The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions, recommending the granting of a marketing authorisation, for Afinitor, Mozobil and Samsca.
|
|
|
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just...
|
